Delic (DELC.C) rebrands recent acquisition CBDV as Delic Labs

Delic Holdings (DELC.C) announced their recently acquired entity Complex Biotech Discovery Ventures (CBDV) has been rebranded as Delic Labs.

Delic Labs is a federally authorized psilocybin and cannabis research laboratory, which has a Section 56 exemption from Health Canada, allowing it to operate a legal shroom lab. This allows them to conduct psilocybin-based research, quality control, and intellectual property development which would otherwise be illegal because of psilocybin’s Schedule III status in Canada.

Delic Labs will also offer advanced analytical testing and extraction optimization for other cannabis companies, on top of running a Cannabis Compound Database, which includes information about more than 750 compounds found in the cannabis plant. This database allows users to find the necessary properties of cannabis compounds and enter the value for any parameter and find all the compounds that match their selection. All their data is verified and updated consistently with the latest research.

“DELIC Labs is the engine of our platform, powering innovation, IP generation and the highest-quality products we can offer our expanding patient base across the country,” stated Matt Stang, Founder and CEO of DELIC. “This rebrand brings the lab further into our self-sustaining ecosystem and ensures patients, investors, partners and our communities understand the connection between the companies and brands that make up our platform.”

As Stang noted, Delic wants Delic Labs to function as the ‘engine’ of their platform, driving innovation and pushing the company forward. They also believe that Delic Labs will bring scalable revenue to the company.

Delic acquired CBDV for $7 million worth of Delic shares at the beginning of this month, and has worked quickly to integrate them into the larger Delic brand umbrella. CBDV was founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis in 2018. Dr. Roggen has a background in organic chemistry and Dr. Sammis’s research focuses on the development of new methods for the syntheses of architecturally complex natural products.

Delic Labs is also applying for a Dealer’s License, with the intention of eventually commercializing its psilocybin research and associated intellectual property.

“We are thrilled to be an integral part of the DELIC platform and provide high-quality research and products to an ever-growing number of patients.” said Dr. Markus Roggen, DELIC Labs’ President and CSO. “The resources and connections the DELIC team brings to our network will help ensure long-term success in psychedelic innovation and technology throughout the world.”

Following today’s announcement, DELC shares are down a cent and a half, and are currently trading at $0.30.

Full disclosure: Delic Holdings is an Equity Guru marketing client.